

30 Patterns of Tipranavir Susceptibility and Cross-Resistance Among Patient Samples Submitted for Routine Resistance Testing

NT Parkin, C Chappey, and E Coakley
 Monogram Biosciences,
 South San Francisco
 CA USA.



XV International HIV Drug Resistance Workshop
 Sitges, Spain
 June 13-17, 2006

Neil T. Parkin
 Monogram Biosciences, Inc.
 345 Oyster Point Blvd.
 South San Francisco, CA 94080
 ntparkin@monogrambio.com

BACKGROUND

- Tipranavir, the most recently approved protease inhibitor (PI), has a favorable activity profile among viruses resistant to other PIs.
- However the relative degree of cross-resistance between tipranavir and other PIs and in samples containing mutation clusters selected by other PIs is not fully understood.

METHODS

- The prevalence and patterns of tipranavir resistance and PI cross-resistance was characterized within a database containing phenotype (PhenoSense HIV) and genotype (GeneSeq HIV) results for 3564 samples containing at least one PI-selected mutation, submitted to the Monogram Clinical Reference Laboratory for routine resistance testing.
 - PI-selected mutations were defined as any non-wild type amino acid at position 23, 24, 30, 32, 46, 47, 48, 50, 54, 82 (except V82I), 84, 88, and 90.
- Samples with mixtures at major resistance-associated positions were removed.
- Only one sample per patient was included if repeats were present.
- Samples with extreme resistance too high to measure (IC_{50} higher than the maximum concentration tested in the assay) were assigned a drug-specific "Max FC" value for calculation purposes
- Samples were classified as tipranavir sensitive (S), partially sensitive (PS), or resistant (R) if the fold change in IC_{50} (FC) was less than the lower cut-off, between the lower and upper cut-off, or over the upper cut-off, respectively (see Table 1). For nelfinavir, the biological cut-off (3.6) was used to define samples as sensitive or having reduced susceptibility.

Table 1. Susceptibility Cut-off Values for Ritonavir-Boosted PIs

PI	Lower		Upper	
	Lower	Upper	Lower	Upper
Ampranavir (APV/r)	4	11.5		
Atazanavir (ATV/r)	5.2	20*		
Indinavir (IDV/r)	10	50*		
Lopinavir (LPV/r)	9	55		
Saquinavir (SQV/r)	2.3	12		
Tipranavir (TPV/r)	2.0	8.0		

*estimated upper cutoff, pending further analysis

Figure 1: Cross Resistance Plots




Table 2: Cross Resistance of Samples Grouped by Susceptibility to TPV (% of all samples)

TPV	2nd PI	2nd PI					
		APV	ATV	IDV	LPV	NFV	SQV
S	S	33%	27%	38%	34%	9.2%	23%
S	PS	10%	14%	15%	13%		19%
S	R	12%	14%	3.2%	46%	14%	14%
PS	S	4.2%	2.4%	6.6%	4.0%	0.9%	3.2%
PS	PS	7.2%	7.1%	16%	11%		8.4%
PS	R	17%	19%	6.2%	14%	28%	17%
R	S	0.3%	0.03%	1.1%	0.3%	0%	0.4%
R	PS	1.4%	1.0%	7.2%	3.1%		2.2%
R	R	14%	15%	7.5%	12%	16%	13%

Figure 2: TPV - LPV Cross Resistance of Samples Grouped by Susceptibility to TPV (left) or LPV (right)




Table 3: PI Susceptibility of Samples Defined by Primary Mutations

Mutation Grouping	TPV				APV				ATV				IDV				LPV				NFV				SQV			
	N	MFC*	S	PS	R	MFC	S	PS	R	MFC	S	PS	R	MFC	S	PS	R	MFC	S	PS	R	MFC	S	PS	R			
D30N	22	0.3	100%	0%	0%	0.7	100%	0%	0%	2.4	95%	4.5%	0%	1.1	100%	0%	0%	0.8	100%	0%	0%	22.7	0%	100%	0.5	100%	0%	0%
D30N_N88D	169	0.9	95%	4.7%	0%	1.0	97%	3.0%	0%	3.7	72%	26%	1.8%	1.8	99%	1.2%	0%	1.1	99%	0.6%	0%	61.7	0%	100%	2.2	54%	44%	1.8%
V32I	6	0.7	100%	0%	0%	2.6	83%	0%	17%	3.2	50%	50%	0%	2.1	100%	0%	0%	1.0	100%	0%	0%	3.8	50%	50%	0.9	100%	0%	0%
V32I_M461L_I47V	8	2.6	13%	88%	0%	9.7	0%	63%	38%	3.7	63%	25%	13%	5.2	75%	25%	0%	9.1	50%	50%	0%	6.5	38%	63%	1.0	88%	13%	0%
M461L	30	1.2	87%	13%	0%	1.1	83%	17%	0%	1.2	97%	3.3%	0%	1.5	97%	3.3%	0%	1.1	97%	3.3%	0%	1.9	77%	23%	0.9	97%	0%	3.3%
IS0V	3	0.3	100%	0%	0%	16.5	0%	33%	67%	1.1	100%	0%	0%	0.7	100%	0%	0%	4.0	100%	0%	0%	1.8	100%	0%	1.2	100%	0%	0%
M461L_IS0V	14	0.4	100%	0%	0%	18.1	0%	36%	64%	0.8	100%	0%	0%	1.0	100%	0%	0%	6.1	71%	29%	0%	2.2	79%	21%	1.2	100%	0%	0%
IS0L	15	1.0	80%	6.7%	13%	1.3	80%	13%	6.7%	24.1	6.7%	4.0%	53%	0.7	100%	0%	0%	0.5	100%	0%	0%	1.3	80%	20%	0.5	93%	6.7%	0%
IS4ALMSTV	21	1.2	71%	29%	0%	4.8	48%	29%	24%	1.9	76%	19%	4.8%	1.2	95%	4.8%	0%	1.7	100%	0%	0%	3.7	43%	57%	1.2	76%	19%	4.8%
V82A	21	1.1	100%	0%	0%	1.2	90%	10%	0%	1.4	95%	4.8%	0%	2.4	100%	0%	0%	2.5	95%	4.8%	0%	2.3	71%	29%	0.9	100%	0%	0%
V82L	4	2.2	50%	50%	0%	1.2	75%	25%	0%	1.6	75%	25%	0%	0.8	100%	0%	0%	1.0	100%	0%	0%	1.3	75%	25%	1.1	75%	25%	0%
V82L +/- others	22	23.5	9.1%	23%	68%	15.8	14%	36%	50%	77.2	14%	18%	68%	23.5	32%	32%	36%	14.6	36%	36%	27%	56.5	18%	82%	7.1	27%	23%	50%
IB4V	20	2.2	45%	50%	5.0%	4.1	50%	40%	10%	3.0	75%	15%	10%	2.9	93%	5.0%	0%	3.0	90%	10%	0%	4.1	45%	55%	5.0	10%	20%	20%
N88S	17	0.9	100%	0%	0%	0.2	100%	0%	0%	17.6	18%	35%	47%	6.1	88%	12%	0%	0.8	100%	0%	0%	24.7	0%	100%	1.7	76%	24%	0%
L90M	298	1.0	91%	9.4%	0%	1.2	95%	4.7%	0.3%	1.8	83%	14%	3.0%	2.3	93%	6.7%	0%	1.2	99%	0.7%	0%	5.9	34%	66%	2.4	48%	44%	8.1%
L24I_M461L_V82A	8	0.6	100%	0%	0%	4.1	50%	38%	13%	4.9	50%	38%	13%	6.8	63%	38%	0%	8.7	50%	50%	0%	6.5	25%	75%	1.2	75%	25%	0%
IS4V_V82A_L90M	63	2.2	43%	54%	3.2%	4.0	48%	38%	14%	11.3	21%	43%	37%	15.0	24%	83%	13%	30.6	4.8%	62%	33%	33.2	0%	100%	10.1	1.6%	38%	60%
M461L_IS4V_V82A_L90M	90	2.8	38%	52%	10%	10.7	16%	38%	47%	27.4	14%	26%	60%	34.4	6%	74%	20%	71.9	0%	36%	64%	57.0	0%	100%	14.0	2.2%	21%	77%
M461L_I47V_IS4V_IB4V_L90M	14	11.4	0%	29%	71%	57.0	0%	0%	100%	181.6	0%	7.1%	93%	147.4	0%	29%	71%	157.8	0%	0%	100%	128.0	0%	100%	100%	0%	0%	100%

*MFC: Median Fold Change in IC_{50}

50-90% >90%

RESULTS SUMMARY

- In the complete data set, 55.6%, 28.6%, and 15.8% of samples were susceptible, partially susceptible, or resistant to TPV/r, respectively.
- Linear regression coefficients (R^2) using log-transformed FC values between TPV and other PIs ranged between 0.27 – 0.40. For comparative purposes, the R^2 value for LPV vs. IDV is 0.75 (Figure 1).
- Among samples PS to TPV/r, the percentage susceptible to other PIs was 14% for APV/r, 8% for ATV/r, 23% for IDV/r, 14% for LPV/r, 3% for NFV, 11% for SQV/r.
- Of samples PS to LPV, the percentage susceptible to other PIs was 26% for APV/r, 16% for ATV/r, 34% for IDV/r, 3% for NFV, 17% for SQV/r, 49% for TPV/r.
- The median FC (MFC) to TPV was less than 2 in samples containing only one primary PI mutation except V82L (MFC 2.4, n=4); the percentage of samples that were PS to TPV was over 25% for IB4V and V82L (Table 3).
- TPV MFC was elevated (2.1 to 2.8) in samples with the following mutation combinations: V32I/M461L/I47V, IS4V/V82A/L90M, and M461L/IS4V/V82A/L90M (n=5, 85, and 56, respectively). In these 3 groups, approximately 60-90% of samples had at least partial TPV resistance, but fewer than 10% were fully resistant (Table 3).

CONCLUSIONS

- Cross resistance between TPV and other approved PIs is lowest with NFV and SQV, highest with APV and ATV, but modest in any case.
- Viruses with single primary mutations remain largely sensitive to TPV, with the exception of IB4V and V82L.

ACKNOWLEDGEMENTS

We are grateful to the Monogram Biosciences Clinical Reference Laboratory for performance of all phenotype and genotype assays.